MDMB-FUBICA

MDMB-FUBICA

Systematic (IUPAC) name
Methyl 2-(1-(4-fluorobenzyl)-1H-indol-3-carboxamide)-3,3-dimethylbutanoate
Clinical data
Legal status	CA: Schedule II
Chemical data
Formula	C23H25FN2O3
Molar mass	396,46 g/mol
SMILES FC1=CC=C(C=C1)CN1C=C(C2=CC=CC=C12)C(=O)NC(C(=O)OC)C(C)(C)C
InChI InChI=1/C23H25FN2O3/c1-23(2,3)20(22(28)29-4)25-21(27)18-14-26(19-8-6-5-7-17(18)19)13-15-9-11-16(24)12-10-15/h5-12,14,20H,13H2,1-4H3,(H,25,27)/f/h25H Key:RVAWIZIGOSKPBP-UHFFFAOYSA-N

MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB₁ receptor and has been sold online as a designer drug.

It was first detected by the EMCDDA in Sweden in February 2015.^[1]

Side effects

MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.^[2]

Legality

MDMB-FUBICA is banned in Sweden.^[3]

See also

• 5F-AB-PINACA
• 5F-ADB
• 5F-AMB
• 5F-APINACA
• AB-FUBINACA
• AB-CHFUPYCA
• AB-CHMINACA
• AB-PINACA
• ADB-CHMINACA
• ADB-FUBINACA
• ADB-PINACA
• AMB-FUBINACA
• APINACA
• APP-FUBINACA
• FUB-APINACA
• MDMB-CHMICA
• MDMB-CHMINACA
• PX-3

References

1. "HAMAROSAN: 2015. ÉVI EURÓPAI KÁBÍTÓSZER - JELENTÉS" (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.
2. "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Retrieved 24 July 2015.
3. "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. 1 June 2015. Retrieved 24 July 2015.